1: Lemmens-Gruber R, Kamyar M. Vasopressin antagonists. Cell Mol Life Sci. 2006 Aug;63(15):1766-79. doi: 10.1007/s00018-006-6054-2. PMID: 16794787; PMCID: PMC11136164.
2: Steinwall M, Bossmar T, Brouard R, Laudanski T, Olofsson P, Urban R, Wolff K, Le-Fur G, Akerlund M. The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor. Gynecol Endocrinol. 2005 Feb;20(2):104-9. doi: 10.1080/09513590400021144. PMID: 15823830.
3: Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008 May 10;371(9624):1624-32. doi: 10.1016/S0140-6736(08)60695-9. PMID: 18468546.
4: Izumi Y, Miura K, Iwao H. Therapeutic potential of vasopressin-receptor antagonists in heart failure. J Pharmacol Sci. 2014;124(1):1-6. doi: 10.1254/jphs.13r13cp. Epub 2014 Jan 7. PMID: 24401675.
5: Cenksoy C, Cenksoy PO, Erdem O, Sancak B, Gursoy R. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model. Eur J Obstet Gynecol Reprod Biol. 2014 Mar;174:86-90. doi: 10.1016/j.ejogrb.2013.12.001. Epub 2013 Dec 12. PMID: 24405730.
6: Brydges NM, Hall J, Best C, Rule L, Watkin H, Drake AJ, Lewis C, Thomas KL, Hall J. Childhood stress impairs social function through AVP-dependent mechanisms. Transl Psychiatry. 2019 Dec 9;9(1):330. doi: 10.1038/s41398-019-0678-0. PMID: 31819033; PMCID: PMC6901493.
7: McDougall ARA, Hastie R, Goldstein M, Tuttle A, Ammerdorffer A, Gülmezoglu AM, Vogel JP. New medicines for spontaneous preterm birth prevention and preterm labour management: landscape analysis of the medicine development pipeline. BMC Pregnancy Childbirth. 2023 Jul 18;23(1):525. doi: 10.1186/s12884-023-05842-9. PMID: 37464260; PMCID: PMC10354994.
8: Lemmens-Gruber R, Kamyar M. Pharmakologie und klinische Bedeutung von Vasopressinantagonisten [Pharmacology and clinical relevance of vasopressin antagonists]. Internist (Berl). 2008 May;49(5):628, 629-30, 632-4. German. doi: 10.1007/s00108-008-2017-z. PMID: 18335184.
9: Zurfluh L, Duvaud L, Inci N, Potterat O, Simões-Wüst AP, Mosbacher J. Bryophyllum pinnatum Inhibits Oxytocin and Vasopressin Signaling in Myometrial Cells. Planta Med. 2024 Aug;90(10):757-765. doi: 10.1055/a-2303-9608. Epub 2024 Apr 10. PMID: 38599625.
10: Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210. doi: 10.1016/s0079-6123(02)39017-4. PMID: 12436936.
11: Haass M. Vaptane und Herzinsuffizienz [Vasopressin receptor antagonists and heart failure]. Ther Umsch. 2009 Nov;66(11):735-40. German. doi: 10.1024/0040-5930.66.11.735. PMID: 19885790.
12: Usta IM, Khalil A, Nassar AH. Oxytocin antagonists for the management of preterm birth: a review. Am J Perinatol. 2011 Jun;28(6):449-60. doi: 10.1055/s-0030-1270111. Epub 2010 Dec 17. PMID: 21170825.
13: Pierzynski P. Oxytocin and vasopressin V(1A) receptors as new therapeutic targets in assisted reproduction. Reprod Biomed Online. 2011 Jan;22(1):9-16. doi: 10.1016/j.rbmo.2010.09.015. Epub 2010 Oct 14. PMID: 21130036.
14: Zhao N, Peacock SO, Lo CH, Heidman LM, Rice MA, Fahrenholtz CD, Greene AM, Magani F, Copello VA, Martinez MJ, Zhang Y, Daaka Y, Lynch CC, Burnstein KL. Arginine vasopressin receptor 1a is a therapeutic target for castration- resistant prostate cancer. Sci Transl Med. 2019 Jun 26;11(498):eaaw4636. doi: 10.1126/scitranslmed.aaw4636. PMID: 31243151; PMCID: PMC7864378.
15: Streefkerk JO, van Zwieten PA. Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents. Auton Autacoid Pharmacol. 2006 Apr;26(2):141-8. doi: 10.1111/j.1474-8673.2006.00361.x. PMID: 16553642.
16: García-Arroyo FE, Muñoz-Jiménez I, Gonzaga G, Tapia E, Osorio-Alonso H, Roncal-Jiménez CA, Iroz A, Vecchio M, Reyes-García JG, Johnson RJ, Sánchez- Lozada LG. A Role for Both V1a and V2 Receptors in Renal Heat Stress Injury Amplified by Rehydration with Fructose. Int J Mol Sci. 2019 Nov 16;20(22):5764. doi: 10.3390/ijms20225764. PMID: 31744099; PMCID: PMC6888540.
17: Garofalo NA, Teixeira Neto FJ, Pereira CD, Pignaton W, Vicente F, Alvaides RK. Cardiorespiratory and neuroendocrine changes induced by methadone in conscious and in isoflurane anaesthetised dogs. Vet J. 2012 Dec;194(3):398-404. doi: 10.1016/j.tvjl.2012.03.019. Epub 2012 Jun 29. PMID: 22750283.
18: Cragg B, Ji G, Neugebauer V. Differential contributions of vasopressin V1A and oxytocin receptors in the amygdala to pain-related behaviors in rats. Mol Pain. 2016 Nov 11;12:1744806916676491. doi: 10.1177/1744806916676491. PMID: 27837170; PMCID: PMC5117246.
19: Erdem Tuncdemir B, Mergen H, Saglar Ozer E. Evaluation of pharmacochaperone- mediated rescue of mutant V2 receptor proteins. Eur J Pharmacol. 2019 Dec 15;865:172803. doi: 10.1016/j.ejphar.2019.172803. Epub 2019 Nov 15. PMID: 31738937.
20: Everett NA, McGregor IS, Baracz SJ, Cornish JL. The role of the vasopressin V1A receptor in oxytocin modulation of methamphetamine primed reinstatement. Neuropharmacology. 2018 May 1;133:1-11. doi: 10.1016/j.neuropharm.2017.12.036. Epub 2018 Jan 17. PMID: 29353054.